Cardiol Therapeutics (CRDL) Receivables - Net (2020 - 2026)

Cardiol Therapeutics' Receivables - Net history runs 7 years deep, the most recent figure standing at $51099.8 for Q1 2026.

• Quarterly Receivables - Net fell 3.47% year-over-year to $51099.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51099.8 (down 3.47% YoY) and the FY2025 annual result came in at $39961.1, down 44.38% from the prior year.
• Receivables - Net was $51099.8 for Q1 2026 at Cardiol Therapeutics, up from $39961.1 in the prior quarter.
• Across five years, Receivables - Net topped out at $154650.9 in Q4 2022 and bottomed at $27244.5 in Q3 2025.
• A 5-year average of $86771.8 and a median of $71846.9 in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net soared 196.53% — and 2024, when it tumbled 68.48%.
• Cardiol Therapeutics' Receivables - Net stood at $154650.9 in 2022, then sank by 32.2% to $104851.3 in 2023, then plunged by 31.48% to $71846.9 in 2024, then sank by 44.38% to $39961.1 in 2025, then climbed by 27.87% to $51099.8 in 2026.
• Business Quant data shows CRDL's Receivables - Net at $51099.8 in Q1 2026, $39961.1 in Q4 2025, and $27244.5 in Q3 2025.